Spin Off
Spin Off
Adaptam Therapeutics is pioneering cancer immunotherapies specifically targeting the immunosuppressive myeloid tumor microenvironment to bring better therapies to oncology patients.
Backed by Criteria Bio Ventures, Adaptam is developing antibody-based therapies directed to novel targets, including glycan-binding proteins and Siglecs, which are expressed in immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs). Adaptam, a spin-off from CIC bioGUNE founded in 2022, has received prestigious national and European grants, including funding from the European Research Council (ERC).
Website: adaptamtx.com/
AKRIBEA is a biotechnology company that provides specialized data analysis services based on nuclear magnetic resonance (NMR) spectroscopy.
The company combines expertise in the life sciences with advanced data processing and modeling techniques to accurately interpret complex molecular profiles from a variety of samples. It offers tailored solutions for metabolomics studies, metabolite quantification, quality control, and compound validation, serving industries such as pharmaceuticals, food science, and biomedical research. Its mission is to transform analytical data into actionable insights that drive scientific innovation and technological development.
ATLAS Molecular Pharma is a biotechnology company focused on the discovery and development of new medicines for the treatment of rare diseases.
We use a very specialized proprietary platform “CHASSYS®” (Chaperone Seeker System) for the identification and validation of active molecules with the appropriate mechanism of action.
This platform allows for the identification of low molecular weight chemical molecules that act as chaperones, therefore improving the folding and/or stabilizing the tertiary structure of proteins that are the cause of a large proportion of rare diseases.
The lead project of the Company is a small molecule for the treatment of Congenital Erythropoietic Porphyria. This molecule has been granted the status of Orphan Drug both by the EMA and the FDA, and is currently in pre-clinical development with the objective to start clinical trials in 2021.
Website: atlasmolecularpharma.com
OWL Metabolomics is a biotechnology company in the field of metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.
OWL has developed a comprehensive set of metabolomics tools, which makes possible the discovery and identification of biomarkers for either research or diagnostics purposes. It is a state of the art technology that combines ultra performance liquid chromatography with mass spectrometry (UPLC-MS). OWL has established a leading position in personalized medicine for liver disease, specifically, non-alcoholic steatohepatitis (NASH) and is currently introducing the first in vitro serum based diagnostic for NAFLD and NASH.
Website: www.owlmetabolomics.com